ROIV vs. INSM, BNTX, TEVA, SMMT, GMAB, ASND, VTRS, RDY, QGEN, and BBIO
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
Roivant Sciences vs. Its Competitors
Insmed (NASDAQ:INSM) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
64.8% of Roivant Sciences shares are held by institutional investors. 3.0% of Insmed shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Insmed currently has a consensus target price of $139.86, suggesting a potential downside of 4.49%. Roivant Sciences has a consensus target price of $17.67, suggesting a potential upside of 23.41%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Insmed.
Roivant Sciences has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Insmed has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Insmed has a net margin of -259.82% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Insmed's return on equity.
In the previous week, Insmed had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 31 mentions for Insmed and 22 mentions for Roivant Sciences. Insmed's average media sentiment score of 1.19 beat Roivant Sciences' score of 0.73 indicating that Insmed is being referred to more favorably in the media.
Summary
Roivant Sciences beats Insmed on 12 of the 17 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ROIV) was last updated on 9/12/2025 by MarketBeat.com Staff
